Literature DB >> 27235476

Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.

Yoav Shetzer1, Alina Molchadsky1, Varda Rotter1.   

Abstract

More than half of human tumors harbor an inactivated p53 tumor-suppressor gene. It is well accepted that mutant p53 shows an oncogenic gain-of-function (GOF) activity that facilitates the transformed phenotype of cancer cells. In addition, a growing body of evidence supports the notion that cancer stem cells comprise a seminal constituent in the initiation and progression of cancer development. Here, we elaborate on the mutant p53 oncogenic GOF leading toward the acquisition of a transformed phenotype, as well as placing mutant p53 as a major component in the establishment of cancer stem cell entity. Therefore, therapy targeted toward cancer stem cells harboring mutant p53 is expected to pave the way to eradicate tumor growth and recurrence.
Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27235476      PMCID: PMC5046690          DOI: 10.1101/cshperspect.a026203

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  204 in total

1.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 2.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

Review 3.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

4.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

Review 5.  Assessing TP53 status in human tumours to evaluate clinical outcome.

Authors:  T Soussi; C Béroud
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

Review 6.  Concise review: mesenchymal tumors: when stem cells go mad.

Authors:  Alexander B Mohseny; Pancras C W Hogendoorn
Journal:  Stem Cells       Date:  2011-03       Impact factor: 6.277

7.  Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9.

Authors:  Jacqueline L Y Chee; Suzan Saidin; David P Lane; Sai Mun Leong; Jacqueline E Noll; Paul M Neilsen; Yi Ting Phua; Hani Gabra; Tit Meng Lim
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 8.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 9.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

10.  Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.

Authors:  P Dong; M Karaayvaz; N Jia; M Kaneuchi; J Hamada; H Watari; S Sudo; J Ju; N Sakuragi
Journal:  Oncogene       Date:  2012-07-30       Impact factor: 9.867

View more
  21 in total

Review 1.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Authors:  Amanda R Wasylishen; Guillermina Lozano
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

Review 2.  AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.

Authors:  Bowen Yan; David Claxton; Suming Huang; Yi Qiu
Journal:  Exp Hematol       Date:  2020-06-20       Impact factor: 3.084

Review 3.  Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Authors:  Miron Prokocimer; Alina Molchadsky; Varda Rotter
Journal:  Blood       Date:  2017-06-12       Impact factor: 22.113

4.  Development of a genetic sensor that eliminates p53 deficient cells.

Authors:  Jovan Mircetic; Antje Dietrich; Maciej Paszkowski-Rogacz; Mechthild Krause; Frank Buchholz
Journal:  Nat Commun       Date:  2017-11-13       Impact factor: 14.919

5.  LSL-KrasG12D; LSL-Trp53R172H/+; Ink4flox/+; Ptf1/p48-Cre mice are an applicable model for locally invasive and metastatic pancreatic cancer.

Authors:  Lixiang Ma; Hexige Saiyin
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

Review 6.  p53 on the crossroad between regeneration and cancer.

Authors:  Meital Charni; Ronit Aloni-Grinstein; Alina Molchadsky; Varda Rotter
Journal:  Cell Death Differ       Date:  2016-10-21       Impact factor: 15.828

Review 7.  Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.

Authors:  Ramona Schulz-Heddergott; Ute M Moll
Journal:  Cancers (Basel)       Date:  2018-06-07       Impact factor: 6.639

8.  Diverse and cancer type‑specific roles of the p53 R248Q gain‑of‑function mutation in cancer migration and invasiveness.

Authors:  Maciej Boleslaw Olszewski; Magdalena Pruszko; Ewa Snaar-Jagalska; Alicja Zylicz; Maciej Zylicz
Journal:  Int J Oncol       Date:  2019-02-22       Impact factor: 5.650

9.  P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.

Authors:  Yuechao Zhao; Yiran Li; Jie Sheng; Fan Wu; Kai Li; Rong Huang; Xiaojuan Wang; Tao Jiao; Xin Guan; Yan Lu; Xiao Chen; Zhiwen Luo; Yanchi Zhou; Hanjie Hu; Wenjie Liu; Boyu Du; Shiying Miao; Jianqiang Cai; Linfang Wang; Hong Zhao; Jianming Ying; Xinyu Bi; Wei Song
Journal:  J Exp Clin Cancer Res       Date:  2019-08-28

10.  LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state.

Authors:  Noa Furth; Ioannis S Pateras; Ron Rotkopf; Vassiliki Vlachou; Irina Rivkin; Ina Schmitt; Deborah Bakaev; Anat Gershoni; Elena Ainbinder; Dena Leshkowitz; Randy L Johnson; Vassilis G Gorgoulis; Moshe Oren; Yael Aylon
Journal:  Life Sci Alliance       Date:  2018-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.